Tingley Whittemore (CIK 1868494) reported 17 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-08-17). Recent activity: Sell TNYA (1,637 shares), Sell TNYA (1,637 shares), Sell TNYA (1,871 shares), Sell TNYA (2,279 shares), Sell TNYA (3,121 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,637 | $1,162 |
| 2026-08-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,637 | $1,162 |
| 2026-08-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,871 | $1,328 |
| 2026-08-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 2,279 | $1,618 |
| 2026-05-19 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 3,121 | $2,477 |
| 2026-02-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,642 | $1,051 |
| 2026-02-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,642 | $1,051 |
| 2026-02-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,876 | $1,201 |
| 2026-02-05 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Buy | 48,750 | $0 |
| 2025-11-17 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 2,877 | $3,826 |
| 2025-08-18 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,608 | $2,010 |
| 2025-08-18 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,608 | $2,010 |
| 2025-08-18 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,837 | $2,296 |
| 2025-05-16 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 2,937 | $1,292 |
| 2025-03-10 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,727 | $933 |
| 2025-03-10 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 4,073 | $2,199 |
| 2025-03-10 | Tenaya Therapeutics, Inc. (TNYA) | Chief Medical Officer | Sell | 1,598 | $863 |
Source: SEC Form 4 filings · as of 2026-08-17